Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3070 - Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Translational Research

Tumour Site

Ovarian Cancer

Presenters

Jung-Yun Lee

Citation

Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285

Authors

J. Lee1, S. Paik2

Author affiliations

  • 1 Gynecologic Cancer Center, Yonsei Cancer Center Yonsei University, 03722 - Seoul/KR
  • 2 Genomics, Yonsei University, 03722 - Seoul/KR
More

Resources

Abstract 3070

Background

Tumor response to NAC predicts survival and can be considered a surrogate prognostic marker. Three tiered chemotherapy response score (CRS) of omental tissue sections showed a significant association with survival. In patients with CRS 1 or 2, NAC selects a subpopulation of chemotherapy resistant tumor cells. Residual tumors remaining after neoadjuvant chemotherapy contain cell population intrinsically resistant to chemotherapy. However, the standard of care for patients who have residual disease after NAC is the same regimen, as therapies that would be effective in reducing recurrences are unknown. We hypothesize that comprehensive molecular analyses of residual disease after NAC measured by targeted sequencing and Immunohistochemistry would be helpful to find out innovate new therapeutic targets.

Methods

During the study period between 2006 and 2017, Pre- and post NAC tumor tissue samples were collected from patients with advanced HGSC. Combined NGS and IHC was performed to identify actionable target and pathway activation in chemo-resistant tumor cells. We examined whether profiling residual HGSC after NAC identifies targetable molecular lesions in the chemotherapy-resistant component of tumor.

Results

Alteration in TP53 were identified in 76 of 104 post-NAC samples (72.1%). HRR gene alteration were found in 30 of 104 post-NAC samples (28.8%). Patients with DNA repair alterations (BRCA1, BRCA2, ATM mutations) were found in 30% of HGSC and they had better chemotherapy sensitivity and survival outcomes than those with intact DNA repair system. Otherwise, rare individual actionable targets (less than 5%) were found in most of patients.

Conclusions

We showed the genomic landscape of drug-resistant tumor cells remaining in advanced HGSC after NAC.

Clinical trial identification

NCT03491033.

Legal entity responsible for the study

Jung-Yun Lee.

Funding

NRF.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.